Technology

The conundrum of missing data vs. inter-rater variability.

In this video interview, Dipanwita Das, CEO & co-founder at Sorcero, looks back to 2024 and discusses some of the industry’s greatest advancements in using artificial intelligence from the previous year.

In this video interview, Dipanwita Das, CEO & co-founder at Sorcero, highlights how artificial intelligence, real-time monitoring, and historical data can aid in optimizing trial design.

How biopharmas are advancing their pharmacovigilance operations.

In this video interview, Kimberly Tableman, founder & CEO, ESPERO, highlights how data standards are empowering the use of artificial intelligence.

In this video interview, Kimberly Tableman, founder & CEO, ESPERO, talks protocol submission formats and how data interoperability can support artificial intelligence.

Pilot trial shows that a user-friendly electronic patient-reported outcome (ePRO) monitoring system significantly improves patient-centered cardiovascular care by enhancing patient-physician communication, increasing clarity in treatment explanations, and empowering patients with better knowledge of their conditions.

Compliance with state telemedicine requirements is imperative, as not only will most clinical trial sponsors contractually require such compliance, but non-compliance may also subject the practitioner to licensure violations and liability.

The emerging solution helps assess how much a therapy being evaluated in a clinical trial can benefit an individual patient.

In this video interview, Sujay Jadhav, CEO of Verana Health, talks AI and its role in optimizing trial design.

Unlocking the full potential of artificial intelligence requires these stakeholders to ensure their data are accessible and secure.

In this video interview, Jane Myles, program director, Decentralized Trials & Research Alliance (DTRA), looks forward and shares her thoughts on future trends with clinical technology.

In this video interview, Jane Myles, program director, Decentralized Trials & Research Alliance (DTRA), highlights how DTRA is working with sites and sponsors to gauge the feasibility of site-validated technology use.

Strategies for sponsors to utilize technology in reaching diverse patient populations.

In this video interview, Jane Myles, program director, Decentralized Trials & Research Alliance (DTRA), highlights challenges with technology adoption including how sites may be asked to work with a variety of different providers.

Balancing these tools with operational efficiencies can aid CROs in meeting the evolving needs of sponsors.

In this video interview, Jane Myles, program director, Decentralized Trials & Research Alliance (DTRA), touches on the adoption of DCT elements and how it can affect study team members.

With the increasing use of artificial intelligence and machine learning in medicine development, what role will they play in the clinical trial space moving forward?

In the fifth and final part of this roundtable discussion, participants discuss the practice of designing technology with patients in mind and share their concluding thoughts on improving diversity in clinical trials.

The three areas poised for a transformation in the advent of electronic clinical outcome assessment technologies.

Use cases spotlight the growing potential of generative AI in the CRO space.

A well-designed approach can benefit clinical trials from protocol design to site support.

Experts weigh in on efforts to realize incremental gains in using AI to ease systemic ills, such as speeding up study enrollment and reducing the risk for unusable flawed data.

The emergence of AI-powered simulants in improving study efficiency.

Mick Ryan, vice president of IT at ICON plc, discusses the growing use of artificial intelligence in clinical research—from technology and data analysis to patient privacy and ethics.